Clinical Trial

Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma

Study acronym: adIVO
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study trial is a prospective, multicentre, exploratory, single-arm, open-label phase II study to evaluat ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma
Protocol Amendment History 2 changes
notable Trial sites expanded: 12 -> 15 locations 2026-08-13
notable Trial sites expanded: 8 -> 12 locations 2026-06-05
Trial Details
NCT Number NCT07260175
Lead Sponsor Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators: Servier Deutschland GmbH, Servier Affaires Médicales
Conditions Cholangiocarcinoma, IDH Mutation
Enrollment 40 participants
Start Date 2025-11-18
Primary Completion 2030-12 (estimated)
Study Completion 2031-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-12